Evaluation of intratympanic formulations for inner ear delivery: Methodology and sustained release formulation testing

Drug Development and Industrial Pharmacy

Volumn 40, Issue 7, 2014, Pages 896-903

  Liu, Hongzhuo ^a,b   Feng, Liang ^a   Tolia, Gaurav ^a   Liddell, Mark R ^a,c   Hao, Jinsong ^a   Li, S Kevin ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c UNITED STATES PHARMACOPEIA   (United States)

Author keywords

Drug release; Inner ear delivery; Intratympanic formulation; Methodology; Temperature responsive gel

Indexed keywords

CIDOFOVIR; COPOLYMER; POLYGLACTIN; ARTIFICIAL MEMBRANE; CYTOSINE; DELAYED RELEASE FORMULATION; DRUG CARRIER; MACROGOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; POLY(LACTIC-CO-GLYCOLIC ACID)-POLYETHYLENE GLYCOL-POLY(LACTIC-CO-GLYCOLIC ACID);

ARTICLE; COCHLEA FENESTRA; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INNER EAR; MIDDLE EAR; SUSTAINED RELEASE FORMULATION; SYNTHESIS; ANALOGS AND DERIVATIVES; ARTIFICIAL MEMBRANE; BIOLOGICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG RELEASE; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES;

CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; CYTOSINE; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG LIBERATION; EAR, INNER; EAR, MIDDLE; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910;

EID: 84902251064     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.789054     Document Type: Article

References (38)

1. Borenstein JT. Intracochlear drug delivery systems. Expert Opin Drug Deliv 2011;8: 1161-74.
2. Swan EE, Mescher MJ, Sewell WF, et al. Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev 2008;60: 1583-99.
3. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther 2004;2: 389-403.
4. Ahmed A. Antiviral treatment of cytomegalovirus infection. Infect Disord Drug Targets 2011;11: 475-503.
5. Rivera T, Sanz L, Camarero G, Varela-Nieto I. Drug delivery to the inner ear: strategies and their therapeutic implications for sensorineural hearing loss. Curr Drug Deliv 2012;9: 231-42.
6. Barrs DM. Intratympanic corticosteroids for Meniere's disease and vertigo. Otolaryngol Clin North Am 2004;37: 955-72.
7. Barrs DM, Keyser JS, Stallworth C, McElveen Jr JT. Intratympanic steroid injections for intractable Meniere's disease. Laryngoscope 2001;111: 2100-4.
8. Dodson KM, Woodson E, Sismanis A. Intratympanic steroid perfusion for the treatment of Meniere's disease: a retrospective study. Ear Nose Throat J 2004;83: 394-8.
9. Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005;26: 878-81.
10. Rauch SD. Intratympanic steroids for sensorineural hearing loss. Otolaryngol Clin North Am 2004;37: 1061-74.
11. Shi J, Yang J, Wu H, et al. Intratympanic dexamethasone medication for sudden sensorineural hearing loss: clinical evaluation. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2006;20: 749-51.
12. Bowe SN, Jacob A. Round window perfusion dynamics: implications for intracochlear therapy. Curr Opin Otolaryngol Head Neck Surg 2010;18: 377-85.
13. McCall AA, Swan EE, Borenstein JT, et al. Drug delivery for treatment of inner ear disease: current state of knowledge. Ear Hear 2010;31: 156-65.
14. Horie RT, Sakamoto T, Nakagawa T, et al. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles. Laryngoscope 2010;120: 377-83.
15. Kelly RM, Meyer JD, Matsuura JE, et al. In vitro release kinetics of gentamycin from a sodium hyaluronate gel delivery system suitable for the treatment of peripheral vestibular disease. Drug Dev Ind Pharm 1999;25: 15-20.
16. Paulson DP, Abuzeid W, Jiang H, et al. A novel controlled local drug delivery system for inner ear disease. Laryngoscope 2008;118: 706-11.
17. Piu F, Wang X, Fernandez R, et al. OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders. Otol Neurotol 2011;32: 171-9.
18. Wang X, Dellamary L, Fernandez R, et al. Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach. Audiol Neurootol 2009;14: 393-401.
19. Koizumi T, Higuchi WI. Analysis of data on drug release from emulsions. II. Pyridine release from water-in-oil emulsions as a function of pH. J Pharm Sci 1968;57: 87-92.
20. Flynn GL, Smith EW. Membrane diffusion. I. Design and testing of a new multifeatured diffusion cell. J Pharm Sci 1971;60: 1713-7.
21. Kneczke M, Landersjo L, Lundgren P, Fuhrer C. In vitro release of salicylic acid from two different qualities of white petrolatum. Acta Pharm Suec 1986;23: 193-204.
22. Emami J. In vitro-in vivo correlation: from theory to applications. J Pharm Pharm Sci 2006;9: 169-89.
23. Qiao M, Chen D, Ma X, Liu Y. Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm 2005;294: 103-12.
24. Azarmi S, Roa W, Lobenberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm 2007; 328: 12-21.
25. Flynn GL, Shah VP, Tenjarla SN, et al. Assessment of value and applications of in vitro testing of topical dermatological drug products. Pharm Res 1999;16: 1325-30.
26. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002;54: 37-51.
27. Zentner GM, Rathi R, Shih C, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001;72: 203-15.
28. Goycoolea MV, Lundman L. Round window membrane. Structure function and permeability: a review. Microsc Res Tech 1997;36: 201-11.
29. Chelikh L, Teixeira M, Martin C, et al. High variability of perilymphatic entry of neutral molecules through the round window. Acta Otolaryngol 2003;123: 199-202.
30. Lundman L, Bagger-Sjoback D, Holmquist L, Juhn S. Round window membrane permeability: an in vitro model. Acta Otolaryngol 1988;457: 73-7.
31. Salt AN, Plontke SK. Principles of local drug delivery to the inner ear. Audiol Neurootol 2009;14: 350-60.
32. Kanzaki S, Fujioka M, Yasuda A, et al. Novel in vivo imaging analysis of an inner ear drug delivery system in mice: comparison of inner ear drug concentrations over time after transtympanic and systemic injections. PLoS One 2012;7:e48480.
33. Wang Y, Gao X, Kuriyavar S, et al. Incorporation, release, and effectiveness of dexamethasone in poly(lactic-co-glycolic acid) nanoparticles for inner ear drug delivery. J Nanotechnol Eng Med 2011;2:011013-1-7.
34. Thaler M, Roy S, Fornara A, et al. Visualization and analysis of superparamagnetic iron oxide nanoparticles in the inner ear by light microscopy and energy filtered TEM. Nanomedicine 2011;7: 360-9.
35. Du X, Chen K, Kuriyavar S, et al. Magnetic targeted delivery of dexamethasone acetate across the round window membrane in guinea pigs. Otol Neurotol 2013;34: 41-7.
36. Mondalek FG, Zhang YY, Kropp B, et al. The permeability of SPION over an artificial three-layer membrane is enhanced by external magnetic field. J Nanobiotechnol 2006;4:4.
37. Lee SH, Lee JE, Baek WY, Lim JO. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Release 2004;96: 1-7.
38. Salt AN, Hartsock J, Plontke S, et al. Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation. Audiol Neurootol 2011;16: 323-35.